Enliven Therapeutics, Inc.
$36.03
-3.9%Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -19.7).
Valuation inputs: P/E -19.7, earnings yield N/A, momentum -3.9%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -22.6%, ROIC -26.0%).
Profitability stack: net margin 0.0%, ROE -22.6%, ROIC -26.0%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +3.5%, momentum -3.9%, net margin 0.0%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Enliven Therapeutics, Inc. Market vs Earnings Trajectory
Loading price and EPS data...
Enliven Therapeutics, Inc. Fair Value Envelope
No Revenue Data
ELVN has not reported any revenue values in the available annual periods.
Enliven Therapeutics, Inc. Profit Bridge
Profitability Analysis
No Gross Profit Margin Data
ELVN has not reported any gross profit margin values in the available annual periods.
No Operating Profit Margin Data
ELVN has not reported any operating profit margin values in the available annual periods.
No Net Profit Margin Data
ELVN has not reported any net profit margin values in the available annual periods.
Enliven Therapeutics, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Moderate conversion rate. Some gap between earnings and cash flow may warrant investigation into working capital or non-cash items.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Flat FCF growth. Stable but not expanding—monitor for signs of business maturity or temporary headwinds.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Enliven Therapeutics, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Enliven Therapeutics, Inc. Street Expectations Map
Wall Street analysts project that ELVN stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 67.00, with estimates ranging from a low of 59.00 to a high of 80.00.
The consensus 1-year price target stands at 67.00, with estimates ranging from a low of 59.00 to a high of 80.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
Good consensus alignment. Moderate target spread reflects general agreement on value drivers with some variance in assumptions.
Analyst Conviction
Positive outlook with reasonable agreement. Analysts generally optimistic about prospects with manageable uncertainty.
Market Sentiment Insight
Monitor and evaluate: Current analyst consensus suggests limited conviction or near-term catalysts. Stay informed on company developments and reassess positioning as new information emerges.
Enliven Therapeutics, Inc. Insider Positioning
During the last 12 months, insiders have sold $7.70M worth of ELVN shares, with no buying activity reported.
3 Months
0
0.00
98.6K
3.19M
-3.2M
-$3.19M
3-6 Months
0
0.00
122.2K
3.18M
-3.2M
-$3.18M
6-9 Months
0
0.00
65.5K
1.33M
-1.3M
-$1.33M
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
No buying activity
Top Sellers
Collins Helen Louise
Officer: Chief Medical Officer
$4.07M
Patel Anish
Officer: Chief Operating Officer
$1.69M
Lyssikatos Joseph P
Officer: Chief Scientific Officer
$1.07M
Kintz Samuel
Director, Officer: President And Ceo
$539K
Hohl Benjamin
Officer: Chief Financial Officer
$304K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $7.70M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
Insider Activity Insight
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
No Dividend Yield Data
ELVN has not reported any dividend yield values in the available annual periods.
elvn Dividend History
Learning Layer
Related Guides
Build conviction on ELVN by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.